Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure

HIV Medicine

Volumn 8, Issue 8, 2007, Pages 504-510

  Svedhem, Veronica ^a   Bergroth, T ^a   Lidman, K ^a   Sonnerborg A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Didanosine; Lamivudine; M184I V; Minor populations; Selective real time PCR

Indexed keywords

ABACAVIR; ADENINE; DIDANOSINE; EFAVIRENZ; GUANINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMINE; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUTANT; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ADULT; AGED; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RNA-DIRECTED DNA POLYMERASE; TREATMENT FAILURE; VIRAL LOAD;

EID: 35448967038     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00502.x     Document Type: Article

References (21)

1. Deeks SG, Hellmann NS, Grant RM et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999; 179: 1375-1381.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
3. Birk M, Svedhem V, Sonnerborg A. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS 2001; 15: 1359-1368.
4. Allers K, Knoepfel SA, Rauch P et al. Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo. J Acquir Immune Defic Syndr 2007; 44: 377-385.
5. Frost SD, Nijhuis M, Schuurman R, Boucher CA, Brown AJ. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection. J Virol 2000; 74: 6262-6268.
6. Martinez-Picado J, Morales-Lopetegi K, Wrin T et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16: 895-899.
7. Schuurman R, Nijhuis M, van Leeuwen R et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995; 171: 1411-1419.
8. Harrigan PR, Stone C, Griffin P et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis 2000; 181: 912-920.
9. Hanna GJ, Johnson VA, Kuritzkes DR et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181: 904-911.
10. Katlama C, Clotet B, Plettenberg A et al. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial. CNA3002 European Study Team. AIDS 2000; 14: 781-789.
11. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992; 66: 7128-7135.
12. Miller V, Sturmer M, Staszewski S et al. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12: 705-712.
13. Vandamme AM, Houyez F, Banhegyi D et al. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther 2001; 6: 21-39.
14. Bergroth T, Sonnerborg A, Yun Z. Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. J Virol Methods 2005; 127: 100-107.
15. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004; 2: 147-151.
16. Karlsson AC, Lindback S, Gaines H, Sonnerborg A. Characterization of the viral population during primary HIV-1 infection. AIDS 1998; 12: 839-847.
17. Rezende LF, Drosopoulos WC, Prasad VR. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase. Nucleic Acids Res 1998; 26: 3066-3072.
18. Sproat M, Pozniak AL, Peeters M et al. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther 2005; 1: 357-361.
19. Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis 2003; 188: 537-540.
20. Petrella M, Oliveira M, Moisi D, Detorio M, Brenner BG, Wainberg MA. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother 2004; 48: 4189-4194.
21. Marcelin AG, Flandre P, Pavie J et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005; 49: 1739-1744.